It’s time for the Lightning Round. Cramer makes the call on viewer favorites.» Read More
Since announcing a merger with Wyeth, drugmaker Pfizer has slipped 13%. So, how should trade healthcare?
I need a break from blogging all-things Pfizer. Sequenom to the rescue with more data on its diagnostic test for Down Syndrome. Out of nearly 900 women there were no false negatives, but for the first time SQNM reported one false positive.
Who's next in the potential wave of consolidation set off by Pfizer and Wyeth? Cramer has an idea.
Paul Noglows, director of research at Lazard Capital Markets, suggested four stock picks in four different sectors that will see growth over the year.
This company could revolutionize pregnancy testing, Cramer says, and make you a ton of money in the process.
The Lightning Round is extended in this CNBC.com exclusive feature.